Comparison of the therapeutic effects of epoetin zeta and epoetin alfa in the correction of renal anaemia

Current Medical Research and Opinion

Volumn 24, Issue 5, 2008, Pages 1407-1415

  Krivoshiev, Stefan ^a   Todorov, Vasil V ^b   Manitius, Jacek ^c   Czekalski, Stanislaw ^d   Scigalla, Paul ^e   Koytchev, Rossen ^f  

^a Multidisciplinary Hospital for Active Treatment 'Queen Giovanna' Ltd   (Bulgaria)

^b Multidisciplinary Hospital for Active Treatment 'Pleven' Ltd   (Bulgaria)

^c Clinic of Nephrology Hypertension and Internal Diseases   (Poland)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^e International Clinical Research Consulting   (Germany)

^f CCDRD AG   (Germany)

Author keywords

Biosimilar; Correction treatment; Efficacy; Epoetin zeta; Erythropoietin; Safety; Therapeutic equivalence

Indexed keywords

EPOETIN ZETA; ERYTHROPOIETIN ANTIBODY; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT HORMONE; RETACRIT; SILAPO;

ADULT; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INFECTION; INFESTATION; INJURY; INTOXICATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; PHASE 3 CLINICAL TRIAL; PURE RED CELL ANEMIA; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE;

ADOLESCENT; ADULT; AGED; ANEMIA; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 44349139462     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X297402     Document Type: Article

References (16)

1. Levin A. Identification of patients and risk factors in chronic kidney disease - evaluating risk factors and therapeutic strategies. Nephrol Dial Transplant 2001;16(Suppl 7):57-60
2. Barbone FP, Johnson DL, Farrell FX, et al. New epoetin molecules and novel therapeutic approaches. Nephrol Dial Transplant 1999;14(Suppl 2):80-4
3. Downey P. Recombinant human erythropoietin as a treatment for anemia of prematurity. J Perinat Neonatal Nurs 1997;11:57-68
4. Jelkmann W. Molecular biology of erythropoietin. Intern Med 2004;43:649-59
5. Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(Suppl 2):ii1-47
6. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 1990;300:573-8
7. European Generic Medicines Agency. Frequently asked questions about biosimilar medicines. Available from http://www.egagenerics.com/FAQ-biosimilars. htm [Last accessed 2 Jan 2008]
8. Macdougall IC. Recent advances in erythropoietic agents in renal anemia. Semin Nephrol 2006;26:313-8
9. Schellekens H. Biosimilar epoetins: how similar are they? Eur J Hosp Pharm 2004;3:43-7
10. European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products. CHMP/437/04. EMEA 2005. Available from http://www.emea.europa.eu/pdfs/human/biosimilar/043704en. pdf [Last accessed 30 Nov 2007]
11. European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues: guidance on similar medicinal products containing recombinant erythropoietins. CHMP/94526/05. EMEA 2006. Available from http://www.emea. europa.eu/pdfs/human/biosimilar/9452605en.pdf [Last accessed 21 Dec 2007]
12. Wizemann V, Rutkowski B, Baldamus C, et al. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment [published erratum in Curr Med Res Opin 2008;24(4):1155]. Curr Med Res Opin 2008;24:625-37
13. Casadevall N, Dupuy E, Molho-Sabatier P, et al. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 1996;334:630-3
14. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-75
15. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987;316:73-8
16. European Directorate for the Quality of Medicines and Healthcare (EDQM). The European Pharmacopoeia. 6th edn. Strasbourg: EDQM, 2007